 BEDFORD, Mass.--BUSINESS WIRE--- OCUL OCUTX--Ocular TherapeutixTM, Inc. Nasdaq: OCUL, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the underwriters of its public offering that closed on December 18, 2020, have exercised in full their option to purchase an additional 558,750 shares of its common stock at the public offering price of 21.50 per share, less underwriting discounts 